secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001493152-24-004964
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Biofrontera sNDA to allow up to 3 tubes of Ameluz per treatment; PDUFA Oct 4, 2024
--------------------------------------------------------------------------------

- FDA completed filing review; target action date October 4, 2024 for Ameluz sNDA to increase max dosage from 1 to 3 tubes per treatment.
- sNDA supported by two Phase 1 safety studies in 32 and 100 patients; systemic and application site AEs similar to 1-tube use.
- Estimated 13M AK treatments annually in US; approval could increase Ameluz utilization by enabling single-visit treatment of larger areas.
- CEO Hermann Luebbert stated potential for more convenient treatment and increased US use if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224004964/0001493152-24-004964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224004964/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-004964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer